Immunotherapy Research Scientist Dr. Bernard Fox Receives International Award for Advancing Innovative Treatments to Cure Cancer
November 10, 2015
Contact: Patricia Pearson, firstname.lastname@example.org, 503.887.1871
FOR IMMEDIATE RELEASE
Washington DC—A Portland, Ore. specialist in the area of immunotherapy and immuno-oncology has been awarded the prestigious Visionary/Legacy Award by the Society for Immunotherapy of Cancer (SITC) at its 30th Anniversary Award Ceremony here. Dr. Bernard A. Fox, PhD, President and Chief Executive Officer, UbiVac, www.ubivac.com, and Harder Family Chair for Cancer Research, at the Earle A Chiles Research Institute, Providence Portland Cancer Center, was lauded for: “His role in advancing the science and application of cancer immunotherapy, his dedication to the SITC and for his distinguished record of service and leadership in the field.”
The awards ceremony was held November 7 with a reception at the Smithsonian National Air and Space Museum.
Dr. Fox co-founded Portland-based UbiVac in 2005, a clinical stage immuno-oncology company, engaged in the development of immunotherapies to combat cancer. In September UbiVac agreed to a collaboration with Johnson & Johnson Innovation to develop and test, in preclinical studies, a vaccine to intercept oral cancer.
Dr. Fox also serves on the board of directors for the Oregon Bioscience Association, is a past president of the SITC, and current chair of the World Immunotherapy Council, a consortium of national and international cancer immunotherapy organizations.
Internationally recognized for his contribution to the development of immunotherapies for various cancers, Dr. Fox has served on advisory boards for Astra Zeneca, Bristol-Meyers Squibb, Cell Genesys, EMD Serono, Janssen/Johnson and Johnson, Novartis, Pfizer, Aduro and others.
The Society for Immunotherapy for Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. Established in 1984, the non-profit entity has a growing constituency of academic, government, industry, clinical and basic scientists, and practitioners from around the world.
UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.